Lineage Historical Income Statement

LCTX Stock

USD 0.57 0.04 6.56%

Historical analysis of Lineage Cell income statement accounts such as Gross Profit of 8.7 M can show how well Lineage Cell Therapeutics performed in making a profits. Evaluating Lineage Cell income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lineage Cell's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lineage Cell Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lineage Cell Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Lineage Income Statement Analysis

Lineage Cell Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lineage Cell shareholders. The income statement also shows Lineage investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Lineage Cell Income Statement Chart

At this time, Lineage Cell's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 20.7 M in 2024.

Total Revenue Other Operating Expenses Cost Of Revenue Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Lineage Cell Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lineage Cell Therapeutics. It is also known as Lineage Cell overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Lineage Cell Therapeutics income statement and represents the costs associated with goods and services Lineage Cell provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Lineage Cell's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	51.7M	36.5M	33.0M	21.0M
Cost Of Revenue	1.4M	728K	671K	583.4K

Total Operating Expenses Cost Of Revenue

Lineage Cell income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Non Recurring	Selling And Marketing Expenses
Depreciation And Amortization		0.3	-0.03	-0.05	0.27	-0.29	-0.26	-0.11	0.2	0.27	-0.28	-0.07	-0.21	-0.17	0.42	0.0	-0.14	-0.69	-0.17	0.39	0.03	-0.59	0.13	0.06	0.06
Interest Expense	0.3		-0.14	-0.13	0.52	-0.56	-0.85	-0.83	-0.16	0.53	0.36	0.79	0.54	-0.93	0.49	0.51	0.64	-0.34	0.58	0.35	0.27	-0.31	0.28	0.12	0.12
Total Revenue	-0.03	-0.14		1.0	-0.07	0.23	0.2	0.2	0.24	-0.07	0.01	-0.18	-0.08	0.16	-0.2	0.06	0.22	-0.32	0.18	0.4	-0.31	0.47	-0.79	-0.51	-0.51
Gross Profit	-0.05	-0.13	1.0		-0.12	0.28	0.21	0.21	0.16	-0.12	0.07	-0.16	-0.04	0.14	-0.25	0.04	0.24	-0.35	0.2	0.42	-0.27	0.48	-0.76	-0.51	-0.51
Other Operating Expenses	0.27	0.52	-0.07	-0.12		-0.94	-0.75	-0.73	0.46	1.0	-0.4	0.38	-0.2	-0.41	0.95	0.88	0.19	0.07	0.26	0.13	0.21	-0.2	0.13	0.29	0.29
Operating Income	-0.29	-0.56	0.23	0.28	-0.94		0.7	0.67	-0.43	-0.94	0.47	-0.3	0.25	0.39	-0.94	-0.76	-0.11	-0.1	-0.16	0.0	-0.21	0.26	-0.25	-0.23	-0.23
Ebit	-0.26	-0.85	0.2	0.21	-0.75	0.7		0.99	-0.03	-0.76	-0.24	-0.86	-0.45	0.89	-0.73	-0.68	-0.61	0.14	-0.6	-0.28	-0.27	0.29	-0.24	-0.18	-0.18
Ebitda	-0.11	-0.83	0.2	0.21	-0.73	0.67	0.99		0.0	-0.74	-0.3	-0.9	-0.5	0.89	-0.68	-0.7	-0.65	0.04	-0.64	-0.23	-0.27	0.21	-0.23	-0.17	-0.17
Cost Of Revenue	0.2	-0.16	0.24	0.16	0.46	-0.43	-0.03	0.0		0.44	-0.59	-0.26	-0.51	0.25	0.53	0.17	-0.33	0.25	-0.27	-0.17	-0.51	-0.08	-0.4	-0.01	-0.01
Total Operating Expenses	0.27	0.53	-0.07	-0.12	1.0	-0.94	-0.76	-0.74	0.44		-0.39	0.39	-0.19	-0.42	0.94	0.88	0.2	0.06	0.27	0.13	0.22	-0.2	0.13	0.28	0.28
Income Before Tax	-0.28	0.36	0.01	0.07	-0.4	0.47	-0.24	-0.3	-0.59	-0.39		0.68	0.96	-0.6	-0.45	-0.22	0.66	-0.14	0.57	0.22	0.01	0.08	-0.02	-0.1	-0.1
Total Other Income Expense Net	-0.07	0.79	-0.18	-0.16	0.38	-0.3	-0.86	-0.9	-0.26	0.39	0.68		0.81	-0.94	0.32	0.44	0.8	-0.06	0.75	0.26	0.21	-0.12	0.17	0.1	0.1
Net Income	-0.21	0.54	-0.08	-0.04	-0.2	0.25	-0.45	-0.5	-0.51	-0.19	0.96	0.81		-0.75	-0.23	-0.08	0.71	-0.1	0.58	0.14	-0.01	-0.05	0.11	-0.03	-0.03
Income Tax Expense	-0.17	-0.93	0.16	0.14	-0.41	0.39	0.89	0.89	0.25	-0.42	-0.6	-0.94	-0.75		-0.38	-0.42	-0.75	0.28	-0.7	-0.36	-0.26	0.28	-0.24	-0.13	-0.13
Research Development	0.42	0.49	-0.2	-0.25	0.95	-0.94	-0.73	-0.68	0.53	0.94	-0.45	0.32	-0.23	-0.38		0.69	0.05	0.04	0.09	0.0	0.1	-0.4	0.23	0.26	0.26
Selling General Administrative	0.0	0.51	0.06	0.04	0.88	-0.76	-0.68	-0.7	0.17	0.88	-0.22	0.44	-0.08	-0.42	0.69		0.39	0.07	0.47	0.28	0.41	0.12	0.05	0.23	0.23
Net Income From Continuing Ops	-0.14	0.64	0.22	0.24	0.19	-0.11	-0.61	-0.65	-0.33	0.2	0.66	0.8	0.71	-0.75	0.05	0.39		-0.21	0.93	0.55	0.16	0.34	-0.27	-0.24	-0.24
Non Operating Income Net Other	-0.69	-0.34	-0.32	-0.35	0.07	-0.1	0.14	0.04	0.25	0.06	-0.14	-0.06	-0.1	0.28	0.04	0.07	-0.21		-0.21	-0.71	-0.32	0.21	0.11	0.27	0.27
Minority Interest	-0.17	0.58	0.18	0.2	0.26	-0.16	-0.6	-0.64	-0.27	0.27	0.57	0.75	0.58	-0.7	0.09	0.47	0.93	-0.21		0.65	0.37	0.38	-0.31	-0.17	-0.17
Tax Provision	0.39	0.35	0.4	0.42	0.13	0.0	-0.28	-0.23	-0.17	0.13	0.22	0.26	0.14	-0.36	0.0	0.28	0.55	-0.71	0.65		0.41	0.15	-0.42	-0.15	-0.15
Interest Income	0.03	0.27	-0.31	-0.27	0.21	-0.21	-0.27	-0.27	-0.51	0.22	0.01	0.21	-0.01	-0.26	0.1	0.41	0.16	-0.32	0.37	0.41		-0.01	0.37	0.2	0.2
Net Interest Income	-0.59	-0.31	0.47	0.48	-0.2	0.26	0.29	0.21	-0.08	-0.2	0.08	-0.12	-0.05	0.28	-0.4	0.12	0.34	0.21	0.38	0.15	-0.01		-0.67	-0.58	-0.58
Reconciled Depreciation	0.13	0.28	-0.79	-0.76	0.13	-0.25	-0.24	-0.23	-0.4	0.13	-0.02	0.17	0.11	-0.24	0.23	0.05	-0.27	0.11	-0.31	-0.42	0.37	-0.67		0.61	0.61
Non Recurring	0.06	0.12	-0.51	-0.51	0.29	-0.23	-0.18	-0.17	-0.01	0.28	-0.1	0.1	-0.03	-0.13	0.26	0.23	-0.24	0.27	-0.17	-0.15	0.2	-0.58	0.61		1.0
Selling And Marketing Expenses	0.06	0.12	-0.51	-0.51	0.29	-0.23	-0.18	-0.17	-0.01	0.28	-0.1	0.1	-0.03	-0.13	0.26	0.23	-0.24	0.27	-0.17	-0.15	0.2	-0.58	0.61	1.0

Click cells to compare fundamentals

Lineage Cell Account Relationship Matchups

Lineage Cell income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	(15.4M)	2.1M	887K	727K	692K	922.5K
Interest Expense	1.7M	5.2M	2K	5.2M	6.0M	6.0M
Total Revenue	1.5M	773K	3.9M	14.7M	8.9M	9.4M
Gross Profit	1.1M	388K	2.5M	14.0M	8.3M	8.7M
Other Operating Expenses	40.4M	27.2M	53.1M	37.2M	33.7M	20.7M
Operating Income	(38.9M)	(26.4M)	(49.2M)	(22.5M)	(24.7M)	(26.0M)
Ebit	(38.9M)	(26.5M)	(49.2M)	(22.5M)	(24.7M)	(26.0M)
Ebitda	(54.3M)	(24.4M)	(48.3M)	(21.8M)	(24.0M)	(25.2M)
Cost Of Revenue	412K	385K	1.4M	728K	671K	583.4K
Total Operating Expenses	39.9M	26.8M	51.7M	36.5M	33.0M	21.0M
Income Before Tax	(19.2M)	(21.9M)	(43.3M)	(25.8M)	(23.3M)	(22.1M)
Total Other Income Expense Net	19.6M	4.5M	5.9M	(3.3M)	1.5M	1.4M
Net Income	(11.8M)	(20.7M)	(38.6M)	(26.4M)	(21.5M)	(20.4M)
Income Tax Expense	(7.4M)	(1.2M)	(4.7M)	541K	(1.8M)	(1.9M)
Research Development	17.9M	12.3M	33.9M	14.0M	15.7M	12.9M
Selling General Administrative	24.0M	15.6M	18.2M	22.5M	17.3M	11.0M
Net Income From Continuing Ops	(26.6M)	(20.7M)	(43.3M)	(26.4M)	(21.5M)	(22.6M)
Non Operating Income Net Other	18.0M	4.5M	5.9M	(4.1M)	(4.7M)	(4.5M)
Net Income Applicable To Common Shares	(11.7M)	(20.6M)	(43.0M)	(26.3M)	(30.2M)	(31.7M)
Minority Interest	(118K)	(36K)	(251K)	(80K)	(7K)	(7.4K)
Tax Provision	(7.4M)	(1.2M)	(2.2M)	541K	(1.8M)	(1.9M)
Interest Income	17.1M	1.0M	2K	829K	1.6M	1.5M
Net Interest Income	1.7M	1.0M	2K	829K	1.6M	1.7M
Reconciled Depreciation	3.1M	2.1M	887K	727K	692K	657.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lineage Historical Income Statement

About Lineage Income Statement Analysis

Lineage Cell Income Statement Chart

Total Revenue

Other Operating Expenses

Cost Of Revenue

Total Operating Expenses

Lineage Cell income statement Correlations

Lineage Cell Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lineage Cell income statement Accounts

Also Currently Popular

Additional Tools for Lineage Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Selling And Marketing Expenses	+ 1.0	Non Recurring
Ebitda	+ 0.99	Ebit
Net Income	+ 0.96	Income Before Tax
Research Development	+ 0.95	Other Operating Expenses

Income Tax Expense	- 0.94	Total Other Income Expense Net
Research Development	- 0.94	Operating Income
Total Operating Expenses	- 0.94	Operating Income
Operating Income	- 0.94	Other Operating Expenses
Income Tax Expense	- 0.93	Interest Expense
Total Other Income Expense Net	- 0.9	Ebitda